Free Trial
NASDAQ:MRSN

Mersana Therapeutics (MRSN) Stock Price, News & Analysis

Mersana Therapeutics logo
$0.34 -0.04 (-9.50%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.35 +0.01 (+2.65%)
As of 07/11/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mersana Therapeutics Stock (NASDAQ:MRSN)

Key Stats

Today's Range
$0.34
$0.39
50-Day Range
$0.28
$0.41
52-Week Range
$0.26
$2.83
Volume
4.52 million shs
Average Volume
2.77 million shs
Market Capitalization
$42.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.20
Consensus Rating
Buy

Company Overview

Mersana Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

MRSN MarketRank™: 

Mersana Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 218th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Mersana Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Mersana Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mersana Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mersana Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Mersana Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.59% of the float of Mersana Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mersana Therapeutics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Mersana Therapeutics has recently decreased by 23.82%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mersana Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Mersana Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.59% of the float of Mersana Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mersana Therapeutics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Mersana Therapeutics has recently decreased by 23.82%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Mersana Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Mersana Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 5 people have searched for MRSN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.00% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mersana Therapeutics' insider trading history.
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Mersana Therapeutics Inc (MRSN) - Investing.com
Q1 2025 Mersana Therapeutics Inc Earnings Call
See More Headlines

MRSN Stock Analysis - Frequently Asked Questions

Mersana Therapeutics' stock was trading at $1.43 at the beginning of 2025. Since then, MRSN shares have decreased by 76.0% and is now trading at $0.3439.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.02. The firm had revenue of $2.75 million for the quarter, compared to the consensus estimate of $6.05 million. Mersana Therapeutics had a negative trailing twelve-month return on equity of 990.16% and a negative net margin of 217.63%.
Read the conference call transcript
.

Mersana Therapeutics (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Saia (SAIA), Rambus (RMBS), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/15/2025
Today
7/12/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRSN
CIK
1442836
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$3.00
Potential Upside/Downside
+1,412.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.19 million
Net Margins
-217.63%
Pretax Margin
-216.41%
Return on Equity
-990.16%
Return on Assets
-48.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.83
Quick Ratio
1.83

Sales & Book Value

Annual Sales
$40.50 million
Price / Sales
1.06
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.08) per share
Price / Book
-4.30

Miscellaneous

Outstanding Shares
124,630,000
Free Float
108,429,000
Market Cap
$42.86 million
Optionable
Optionable
Beta
0.79

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:MRSN) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners